BlackRock’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

BlackRock’s Portfolio IMNP Stock Details IMNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-568	Closed	–	–	5164
2018 Q2	$0	Hold	568	–	–	﹤0.01%	5143
2018 Q1	$0	Hold	568	–	–	﹤0.01%	5069
2017 Q4	$0	Hold	568	–	–	﹤0.01%	5048
2017 Q3	$1K	Hold	568	–	–	﹤0.01%	4943
2017 Q2	$2K	Buy	568 +17	+3%	+$46	﹤0.01%	4927
2017 Q1	$2K	Buy	+551	New	+$1.99K	﹤0.01%	4916

Other funds holding IMNP

Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return

BlackRock's IMNP Position: Q3 2018 in Review

BlackRock sold out of Immune Pharmaceuticals Inc. (IMNP) in Q3 2018, closing a stake of 568 shares.

BlackRock first reported a position in IMNP in Q1 2017 and held it in 6 quarters. The position peaked at $2K in Q2 2017. 1 fund tracked by Wall St. Rank holds IMNP as of Q3 2018.

BlackRock reported no remaining Immune Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
BlackRock sold 568 Immune Pharmaceuticals Inc. shares in Q3 2018.
BlackRock first reported a position in Immune Pharmaceuticals Inc. in Q1 2017 and held it in 6 quarters.
BlackRock's Immune Pharmaceuticals Inc. position peaked at $2K in Q2 2017.
1 fund tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q3 2018.

Based on BlackRock's 13F filing for Q3 2018, filed 9 Nov 2018.